Biotechnology News and Research

RSS

Brain Tumor Biotech Summit held in Manhattan on 29 May, 2015

Voices Against Brain Cancer, a national non-profit organization committed to finding a cure for brain cancer and brain tumors, and the Feinstein Institute for Medical Research in Long Island, will be hosting a Brain Tumor Biotech Summit on Friday, May 29th, 2015 at Lenox Hill Hospital's Einhorn Auditorium in Manhattan.

30 May 2015

Ventana, Halozyme partner to develop companion diagnostic assay for cancer treatment

Halozyme Therapeutics, Inc. and Ventana Medical Systems, Inc., a member of the Roche Group, announced today a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20

30 May 2015

FVCG portfolio companies selected to present research at Bio International 2015

Actinobac Biomed, NovoPedics, Inc. and MentiNova, Inc., three biotech start-up companies originally funded with investments from Foundation Venture Capital Group (FVCG), have been selected to present their research at Bio International 2015 as part of the Start-Up Stadium and Company Presentation forums offered at the Conference, announced FVCG President James M. Golubieski.

30 May 2015

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Arnaud Foussat, VP Research and New Products, TxCell, will deliver two presentations at the 21st Annual Meeting of the International Society of Cellular Therapy, May 27-30, 2015, in Las Vegas, Nevada, US.

30 May 2015

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the three months ended March 31, 2015 and updates on its drug development programs.

29 May 2015

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen today announced pooled data from two pivotal Phase 3, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic, for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) receiving hemodialysis.

29 May 2015

Amgen creates catalog of qualified tools and reagents to advance basic discoveries in biology

Amgen today announced the creation of a catalog of qualified tools and reagents available to academic institutions to help further research and advance basic discoveries in biology, as well as deepen relationships with academic institutions.

29 May 2015

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology Corp. announces preliminary data showing that PDS0101, a cancer immunotherapy treatment targeting HPV-16, has generated strong T-cell responses in pre-cervical cancer patients.

28 May 2015

TxCell reports results from annual general meeting of shareholders

28 May 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.

28 May 2015

Six research teams awarded grant to accelerate discovery of new drugs for brain, nervous system disorders

CQDM, Brain Canada and the Ontario Brain Institute award close to $8.5M to six (6) multi-disciplinary and multi-provincial research teams across Canada to address unmet needs in neuroscience within their Focus on Brain strategic initiative. To this amount, $1.5M is added from the various research entities involved as in-kind contributions.

27 May 2015

Ceres receives U.S. patent for genetic sequence obtained from soybean

Ceres, Inc., an agricultural biotechnology company, has been awarded a U.S. patent for a genetic sequence derived from soybean, covering uses of the gene in areas such as research, product development and plant transformation.

27 May 2015

Scorpion venom could kill cancer cells

When the toxin invades channels in the cells with this disease produces cellular damage until killing them.

27 May 2015

New tool could help identify pathogens in food and beverages

Researchers at the National Polytechnic Institute (IPN) in Mexico, developed a technology capable of identifying pathogens in food and beverages. This technique could work in the restaurant industry as a biosensor to detect in what conditions food is before being eaten in order to avoid possible gastrointestinal diseases.

27 May 2015

Study explores how our intestinal tract changes as we age

Scientists and clinicians on the Norwich Research Park have carried out the first detailed study of how our intestinal tract changes as we age, and how this determines our overall health.

22 May 2015

Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression.

21 May 2015

Discovery Lab enrolls first patient in phase 2a clinical trial of AEROSURF

Discovery Laboratories, Inc., a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today reported that the first patient has been enrolled in the next phase of its phase 2a clinical evaluation of AEROSURF, which is designed to evaluate the safety and tolerability of higher and repeat doses of aerosolized KL4 surfactant administered to premature infants 29 to 34 weeks gestational age (GA) who are receiving nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS), compared to infants receiving nCPAP alone.

20 May 2015

DNAtrix signs agreement to utilize Alcyone's MEMS platform for direct drug delivery into glioblastoma

Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).

19 May 2015

ORIG3N, LabCorp form strategic partnership

ORIG3N, Inc., a pioneer in regenerative medicine and provider of induced pluripotent stem cell (iPSC) storage, called LifeCapsule, today announced a strategic collaboration with Laboratory Corporation of America Holdings.

19 May 2015

Cryoport net revenues increase 44% to $1.2 million in fourth quarter 2015

Cryoport, Inc. today announced financial results for the three and twelve-month periods ended March 31, 2015.

19 May 2015

Biotechnology News and Research

Brain Tumor Biotech Summit held in Manhattan on 29 May, 2015

Ventana, Halozyme partner to develop companion diagnostic assay for cancer treatment

FVCG portfolio companies selected to present research at Bio International 2015

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen creates catalog of qualified tools and reagents to advance basic discoveries in biology

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

TxCell reports results from annual general meeting of shareholders

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Six research teams awarded grant to accelerate discovery of new drugs for brain, nervous system disorders

Ceres receives U.S. patent for genetic sequence obtained from soybean

Scorpion venom could kill cancer cells

New tool could help identify pathogens in food and beverages

Study explores how our intestinal tract changes as we age

Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

Discovery Lab enrolls first patient in phase 2a clinical trial of AEROSURF

DNAtrix signs agreement to utilize Alcyone's MEMS platform for direct drug delivery into glioblastoma

ORIG3N, LabCorp form strategic partnership

Cryoport net revenues increase 44% to $1.2 million in fourth quarter 2015

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News